Compounds for use in inducing myocardial perfusion recovery
AssigneeEpoqe Pharma ApS
InventorsAnette Sams Nielsen, Lars Ingvar Herbert Edvinsson
Life of this patent
Estimating the term…
Abstract
A calcitonin gene-related peptide (CGRP) compound can be selected from N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)-butyrylamino]ethoxy}ethoxy)acetyl][Ser1]alpha-human CGRP peptide (α-CGRP-analogue), or derivatives thereof; or N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyryl-amino]-ethoxy}ethoxy)acetyl][Ser1]beta-human CGRP peptide (β-CGRP-analogue), or derivatives thereof. The CGRP compound can be used to induce myocardial perfusion recovery, in connection with AMI, by activating any CGRP family of receptors with a larger CGRP compound: CGRP potency ratio in the coronary artery than in the mesenteric artery.
Claims15
A method for the treatment of acute myocardial infarction (AMI), the method comprising:
- administering a calcitonin gene-related peptide (CGRP) compound,
- wherein the CGRP compound is N-alpha-[2-(2-{2-[(S)]-4-carboxy-4-(17-carboxyheptadecanoylamino)-butyryl-amino]-ethoxy}ethoxy)acetyl][Ser1]beta-human CGRP peptide (β-CGRP-analogue), and a pharmaceutically acceptable salts and solvates thereof,
- wherein the CGRP compound is administered at least once per day, and
- wherein the CGRP is administered for one to thirty consecutive days immediately after incident.
Dependencies are inferred from the claim text.